阿巴西普治疗 B7-1 阳性蛋白尿性肾病。
Abatacept in B7-1-positive proteinuric kidney disease.
出版信息
N Engl J Med. 2014 Mar 27;370(13):1263-6. doi: 10.1056/NEJMc1400502.
Abstract
Abatacept (cytotoxic T-lymphocyte–associated antigen 4–immunoglobulin fusion protein [CTLA-4–Ig]) is a costimulatory inhibitor that targets B7-1 (CD80). The present report describes five patients who had focal segmental glomerulosclerosis (FSGS) (four with recurrent FSGS after transplantation and one with primary FSGS) and proteinuria with B7-1 immunostaining of podocytes in kidney-biopsy specimens. Abatacept induced partial or complete remissions of proteinuria in these patients, suggesting that B7-1 may be a useful biomarker for the treatment of some glomerulopathies. Our data indicate that abatacept may stabilize 1-integrin activation in podocytes and reduce proteinuria in patients with B7-1–positive glomerular disease.
摘要
阿巴西普（细胞毒性 T 淋巴细胞相关抗原 4-免疫球蛋白融合蛋白 [CTLA-4-Ig]）是一种靶向 B7-1（CD80）的共刺激抑制剂。本报告描述了 5 例患有局灶节段性肾小球硬化症（FSGS）（4 例为移植后复发性 FSGS，1 例为原发性 FSGS）和蛋白尿的患者，其肾脏活检标本中足细胞有 B7-1 免疫染色。阿巴西普诱导这些患者的蛋白尿部分或完全缓解，提示 B7-1 可能是治疗某些肾小球疾病的有用生物标志物。我们的数据表明，阿巴西普可能稳定足细胞中 1 整合素的激活，并减少 B7-1 阳性肾小球疾病患者的蛋白尿。
相似文献
1
Abatacept in B7-1-positive proteinuric kidney disease.阿巴西普治疗 B7-1 阳性蛋白尿性肾病。
N Engl J Med. 2014 Mar 27;370(13):1263-6. doi: 10.1056/NEJMc1400502.
2
Abatacept in B7-1-positive proteinuric kidney disease.阿巴西普治疗B7-1阳性蛋白尿性肾病
N Engl J Med. 2014 Mar 27;370(13):1261-3. doi: 10.1056/NEJMc1400502.
3
Abatacept in B7-1-positive proteinuric kidney disease.阿巴西普治疗B7-1阳性蛋白尿性肾病
N Engl J Med. 2014 Mar 27;370(13):1263-4. doi: 10.1056/NEJMc1400502.
4
A new era of podocyte-targeted therapy for proteinuric kidney disease.蛋白尿性肾病足细胞靶向治疗的新时代。
N Engl J Med. 2013 Dec 19;369(25):2453-4. doi: 10.1056/NEJMe1312835. Epub 2013 Nov 8.
5
Abatacept in B7-1-positive proteinuric kidney disease.阿巴西普治疗 B7-1 阳性蛋白尿性肾病。
N Engl J Med. 2013 Dec 19;369(25):2416-23. doi: 10.1056/NEJMoa1304572. Epub 2013 Nov 8.
6
Podocyte-Targeted Treatment for Proteinuric Kidney Disease.足细胞靶向治疗蛋白尿性肾病
Semin Nephrol. 2016 Nov;36(6):459-462. doi: 10.1016/j.semnephrol.2016.09.008.
7
Efficacy of abatacept treatment for focal segmental glomerulosclerosis and minimal change disease: A systematic review of case reports, case series, and observational studies
.阿巴西普治疗局灶节段性肾小球硬化和微小病变病的疗效：病例报告、病例系列及观察性研究的系统评价
Clin Nephrol. 2020 Sep;94(3):117-126. doi: 10.5414/CN110134.
8
The role of B7-1 in proteinuria of glomerular origin.B7-1 在肾小球源性蛋白尿中的作用。
Nat Rev Nephrol. 2018 Sep;14(9):589-596. doi: 10.1038/s41581-018-0037-z.
9
Successful Treatment With Abatacept in Recurrent Focal Segmental Glomerulosclerosis After Kidney Transplant.肾移植后复发性局灶节段性肾小球硬化症使用阿巴西普治疗成功
Exp Clin Transplant. 2019 Jan;17(Suppl 1):178-180. doi: 10.6002/ect.MESOT2018.P53.
10
The costimulatory receptor B7-1 is not induced in injured podocytes.共刺激受体B7-1在损伤的足细胞中未被诱导。
Kidney Int. 2016 Nov;90(5):1037-1044. doi: 10.1016/j.kint.2016.06.022. Epub 2016 Aug 12.
引用本文的文献
1
Research progress of CD80 in the development of immunotherapy drugs.CD80 在免疫治疗药物发展中的研究进展。
Front Immunol. 2024 Nov 7;15:1496992. doi: 10.3389/fimmu.2024.1496992. eCollection 2024.
2
Development of a novel tool for individual treatment trials in mucopolysaccharidosis.一种用于黏多糖贮积症个体治疗试验的新型工具的研发。
J Inherit Metab Dis. 2025 Jan;48(1):e12816. doi: 10.1002/jimd.12816. Epub 2024 Nov 21.
3
Ferroptosis-related genes, a novel therapeutic target for focal segmental glomerulosclerosis.铁死亡相关基因：局灶节段性肾小球硬化症的新治疗靶点。
BMC Nephrol. 2024 Feb 17;25(1):58. doi: 10.1186/s12882-024-03490-5.
4
Immune podocytes in the immune microenvironment of lupus nephritis (Review).狼疮肾炎免疫微环境中的免疫足细胞（综述）。
Mol Med Rep. 2023 Nov;28(5). doi: 10.3892/mmr.2023.13091. Epub 2023 Sep 15.
5
B7-1 mediates podocyte injury and glomerulosclerosis through communication with Hsp90ab1-LRP5-β-catenin pathway.B7-1 通过与热休克蛋白 90ab1-LRP5-β-连环蛋白通路的通讯介导足细胞损伤和肾小球硬化。
Cell Death Differ. 2022 Dec;29(12):2399-2416. doi: 10.1038/s41418-022-01026-8. Epub 2022 Jun 16.
6
Benefit of B7-1 staining and abatacept for treatment-resistant post-transplant focal segmental glomerulosclerosis in a predominantly pediatric cohort: time for a reappraisal.在以儿童为主的队列中，B7-1染色及阿巴西普治疗移植后难治性局灶节段性肾小球硬化的益处：是时候重新评估了。
Pediatr Nephrol. 2023 Jan;38(1):145-159. doi: 10.1007/s00467-022-05549-7. Epub 2022 May 4.
7
The immune cell landscape of peripheral blood mononuclear cells from PNS patients.周围血单个核细胞中 PNS 患者的免疫细胞图谱。
Sci Rep. 2021 Jun 22;11(1):13083. doi: 10.1038/s41598-021-92573-6.
8
IGFBP-1 expression is reduced in human type 2 diabetic glomeruli and modulates β1-integrin/FAK signalling in human podocytes.IGFBP-1 的表达在人 2 型糖尿病肾小球中减少，并调节人足细胞中的 β1-整合素/FAK 信号通路。
Diabetologia. 2021 Jul;64(7):1690-1702. doi: 10.1007/s00125-021-05427-1. Epub 2021 Mar 24.
9
Combination CTLA-4 immunoglobulin treatment and ultrasound microbubble-mediated exposure improve renal function in a rat model of diabetic nephropathy.联合 CTLA-4 免疫球蛋白治疗和超声微泡介导的暴露可改善糖尿病肾病大鼠模型的肾功能。
Aging (Albany NY). 2021 Mar 10;13(6):8524-8540. doi: 10.18632/aging.202664.
10
Nephrin Signaling in the Podocyte: An Updated View of Signal Regulation at the Slit Diaphragm and Beyond.足细胞中的Nephrin信号传导：裂孔隔膜及其他部位信号调节的最新观点
Front Endocrinol (Lausanne). 2018 Jun 5;9:302. doi: 10.3389/fendo.2018.00302. eCollection 2018.
本文引用的文献
1
Abatacept in the treatment of lupus.阿巴西普治疗狼疮。
Expert Opin Biol Ther. 2012 Oct;12(10):1399-406. doi: 10.1517/14712598.2012.713934. Epub 2012 Aug 7.
2
Focal segmental glomerulosclerosis.局灶节段性肾小球硬化症
N Engl J Med. 2011 Dec 22;365(25):2398-411. doi: 10.1056/NEJMra1106556.
3
Cell biology and pathology of podocytes.足细胞的细胞生物学和病理学。
Annu Rev Physiol. 2012;74:299-323. doi: 10.1146/annurev-physiol-020911-153238. Epub 2011 Nov 4.
4
Rheumatoid arthritis.类风湿关节炎。
Lancet. 2010 Sep 25;376(9746):1094-108. doi: 10.1016/S0140-6736(10)60826-4.
5
The final steps of integrin activation: the end game.整合素激活的最后步骤：终局。
Nat Rev Mol Cell Biol. 2010 Apr;11(4):288-300. doi: 10.1038/nrm2871.
6
M-type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy.M型磷脂酶A2受体作为特发性膜性肾病的靶抗原
N Engl J Med. 2009 Jul 2;361(1):11-21. doi: 10.1056/NEJMoa0810457.
7
PD-1 and its ligands in tolerance and immunity.PD-1及其配体在免疫耐受与免疫中的作用
Annu Rev Immunol. 2008;26:677-704. doi: 10.1146/annurev.immunol.26.021607.090331.
8
New therapies for treatment of rheumatoid arthritis.类风湿关节炎的新疗法
Lancet. 2007 Dec 1;370(9602):1861-74. doi: 10.1016/S0140-6736(07)60784-3.
9
Synaptopodin protects against proteinuria by disrupting Cdc42:IRSp53:Mena signaling complexes in kidney podocytes.突触足蛋白通过破坏肾足细胞中的Cdc42:IRSp53:Mena信号复合物来预防蛋白尿。
Am J Pathol. 2007 Aug;171(2):415-27. doi: 10.2353/ajpath.2007.070075. Epub 2007 Jun 14.
10
Structural basis of integrin activation by talin.踝蛋白激活整合素的结构基础。
Cell. 2007 Jan 12;128(1):171-82. doi: 10.1016/j.cell.2006.10.048.
Zotero 插件